Krystal Biotech (NASDAQ:KRYS) Releases Quarterly Earnings Results, Beats Estimates By $0.21 EPS

Key Points

• Krystal Biotech's quarterly earnings report revealed an EPS of $1.29, surpassing expectations by $0.09.
• The company boasts a market capitalization of $4.54 billion with a return on equity of 14.64% and a net margin of 37.17%.
• Wall Street analysts maintain a consensus rating of "Buy" for KRYS, with an average price target of $211.33.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) released its quarterly earnings data on Monday. The company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.21, Zacks reports. Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. The company had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million.

Krystal Biotech Trading Down 13.8%

Shares of NASDAQ KRYS traded down $21.61 during mid-day trading on Monday, hitting $135.37. The company had a trading volume of 967,348 shares, compared to its average volume of 323,832. The company has a market capitalization of $3.91 billion, a price-to-earnings ratio of 32.46 and a beta of 0.70. Krystal Biotech has a 1 year low of $122.80 and a 1 year high of $207.84. The stock's 50-day moving average price is $140.83 and its 200-day moving average price is $155.89.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the firm's stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the sale, the insider owned 1,508,056 shares in the company, valued at $226,208,400. This trade represents a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 49,800 shares of company stock worth $7,487,943 over the last three months. 13.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of KRYS. AQR Capital Management LLC boosted its holdings in shares of Krystal Biotech by 29.9% during the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company's stock worth $2,187,000 after purchasing an additional 2,792 shares during the period. Empowered Funds LLC bought a new position in Krystal Biotech in the first quarter worth about $218,000. Royal Bank of Canada raised its stake in Krystal Biotech by 145.2% in the first quarter. Royal Bank of Canada now owns 1,628 shares of the company's stock worth $294,000 after buying an additional 964 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Krystal Biotech by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company's stock worth $2,870,000 after buying an additional 688 shares in the last quarter. 86.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on KRYS. Citigroup reiterated a "neutral" rating and issued a $176.00 price objective (up previously from $155.00) on shares of Krystal Biotech in a report on Wednesday, July 9th. Guggenheim dropped their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Chardan Capital reissued a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a research report on Friday, July 25th. Bank of America decreased their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Finally, HC Wainwright reissued a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research report on Friday, July 25th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $211.33.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).